Previous 10 | Next 10 |
Palm Beach, FL – February 22, 2023 – FinancialNewsMedia.com News Commentary – Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of cancer that mainly occurs in white blood cells. White bloo...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time to start another day of trading with a breakdown of the biggest pre-market stock movers for Tuesday! Moving stocks this morning are a $30 million private placement,...
Actinium Pharmaceuticals ( NYSE: ATNM ) added ~13% pre-market Monday after announcing its pivotal Phase 3 trial for lead candidate Iomab-B reached the primary endpoint in active relapsed or refractory acute myeloid leukemia (r/r AML). The 153-patient SIERRA trial was designed to e...
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia PR Newswire - Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial compl...
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023 Actinium to Present Full Results from Pivotal Phase 3 Iom...
Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies PR Newswire - National Cancer I...
Summary Today, we take our first new look at a small developmental firm called Actinum Pharmaceuticals in nearly two years. The company posted promising results from a pivotal trial around its lead candidate in October and should soon submit a Biologic License Application around the com...
Actinium Pharmaceuticals, Inc. to Present at the 3rd Annual B. Riley Securities Oncology Conference PR Newswire NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the developmen...
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem ...
Summary Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators. The sell-off over the data delay is overdone. Shares have drifted down from a November high of $14.41 to $9.88, offering an interest...
News, Short Squeeze, Breakout and More Instantly...
Actinium Pharmaceuticals Inc. Company Name:
ATNM Stock Symbol:
NYSE Market:
Actinium Pharmaceuticals Inc. Website:
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, fe...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com , a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and ...